- Home
- NRT vs FGEN Comparison
NRT vs FGEN Comparison
Compare NRT & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRT
- FGEN
- Stock Information
- Founded
- NRT 1975
- FGEN 1993
- Country
- NRT United States
- FGEN United States
- Employees
- NRT N/A
- FGEN N/A
- Industry
- NRT Oil & Gas Production
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NRT Energy
- FGEN Health Care
- Exchange
- NRT Nasdaq
- FGEN Nasdaq
- Market Cap
- NRT 44.0M
- FGEN 33.5M
- IPO Year
- NRT N/A
- FGEN 2014
- Fundamental
- Price
- NRT $4.85
- FGEN $7.26
- Analyst Decision
- NRT
- FGEN Strong Buy
- Analyst Count
- NRT 0
- FGEN 1
- Target Price
- NRT N/A
- FGEN $250.00
- AVG Volume (30 Days)
- NRT 17.3K
- FGEN 74.1K
- Earning Date
- NRT 08-29-2025
- FGEN 08-05-2025
- Dividend Yield
- NRT 9.80%
- FGEN N/A
- EPS Growth
- NRT 24.05
- FGEN N/A
- EPS
- NRT 0.59
- FGEN N/A
- Revenue
- NRT $6,184,173.00
- FGEN $6,996,000.00
- Revenue This Year
- NRT N/A
- FGEN N/A
- Revenue Next Year
- NRT N/A
- FGEN N/A
- P/E Ratio
- NRT $8.34
- FGEN N/A
- Revenue Growth
- NRT 18.55
- FGEN N/A
- 52 Week Low
- NRT $3.88
- FGEN $4.50
- 52 Week High
- NRT $6.90
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- NRT 41.85
- FGEN 60.54
- Support Level
- NRT $4.80
- FGEN $5.37
- Resistance Level
- NRT $5.20
- FGEN $5.73
- Average True Range (ATR)
- NRT 0.16
- FGEN 0.49
- MACD
- NRT -0.04
- FGEN 0.27
- Stochastic Oscillator
- NRT 15.40
- FGEN 83.80
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.